ABLIM3 Antibody

Structure and Function of ABLIM3

ABLIM3 contains a LIM domain, a double zinc finger motif that facilitates protein-protein interactions . Its primary functions include:

• Cytoskeleton regulation: Interacting with actin filaments to maintain cellular structure .

• Cell adhesion: Contributing to adherens junction stability, which regulates epithelial integrity .

• Cancer progression: Implicated in metastasis mechanisms, particularly in neuroblastoma, where low ABLIM3 expression correlates with poor prognosis .

Research Applications

ABLIM3 antibodies are employed in diverse experimental workflows:

• Western Blotting (WB):
  Used to quantify ABLIM3 protein levels in lysates from neuroblastoma cell lines (e.g., SK-N-AS, SK-N-BE2) . Example: ABLIM3 knockdown via shRNA in NB cells reduced ITGA3, ITGA8, and KRT19 expression, enhancing metastatic potential .

• Immunohistochemistry (IHC):
  Localizes ABLIM3 in tumor tissues, revealing its downregulation in metastatic neuroblastoma samples .

• Immune Microenvironment Analysis:
  Correlates ABLIM3 expression with tumor-infiltrating immune cells, such as CD4+ T cells and macrophages, using tools like CIBERSORT .

4.1. Role in Neuroblastoma Metastasis

• ABLIM3 downregulation promotes NB cell migration and invasion by disrupting cell adhesion molecules (CAMs) .

• TIDE analysis indicates low ABLIM3 expression predicts poor responses to immunotherapy in NB patients .

4.2. Mechanistic Insights

• ABLIM3 interacts with ABRA to regulate actin dynamics and transcriptional activity .

• Loss of ABLIM3 impairs adherens junctions, increasing epithelial permeability .

Clinical Relevance

ABLIM3 antibody-based studies highlight its potential as:

• Prognostic biomarker: Low expression correlates with aggressive neuroblastoma phenotypes .

• Therapeutic target: Modulating ABLIM3 levels may inhibit metastasis or enhance immunotherapy efficacy .

Limitations and Future Directions

While ABLIM3 antibodies enable robust protein detection, further studies are needed to:

• Validate in vivo models of cancer progression.

• Explore therapeutic agents targeting ABLIM3 pathways .